BAX · Baxter International Inc
Price & Indicators
Up next
Metrics snapshot
Useful current figures from the complete screener profile.
AI Brief
Q2 FY26 earnings call · Jul 30, 2026TL;DR. Baxter reported Q2 sales of $2.96B (up 5% reported and organic), beating expectations and driven by broad-based growth including a $75M IEEPA tariff refund not in prior guidance; the company raised full-year 2026 reported sales growth to 3-4%, organic sales to 2-3%, and adjusted EPS to $1.95-$2.15 from $1.85-$2.05.
- + Raised full-year 2026 adjusted EPS guidance to $1.95-$2.15 from $1.85-$2.05, reflecting the Q2 tariff refund
- + Advanced Surgery sales grew 12% to $331M on continued strong global demand for hemostats and sealants
- − Q2 adjusted EPS of $0.56 declined 5% YoY due to higher-cost inventory roll-through and unfavorable prior-year comparison
- − MPT segment adjusted operating margin fell 350 bps to 19.3% on higher manufacturing costs and Section 232 tariff impact
- − Adjusted gross margin contracted 210 bps to 38.6% and adjusted operating margin fell 90 bps to 14.2%
- − Novum IQ LVP remains on shipment and installation hold, pressuring Infusion Systems sales and creating customer uncertainty
- − Supply constraints on injectables from a contract manufacturer and softness in pre-mixed products continue to weigh on results
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Medical Instruments & Supplies — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
BAX
this stock
Baxter International Inc
|
$12.14B | +26.7% | +5.7% | — | 4.5% |
|
ISRG
Intuitive Surgical Inc
|
$143.14B | -28.2% | +20.5% | 46.5 | 2.3% |
|
BDX
Becton Dickinson & Co
|
$49.57B | — | +8.2% | — | 4.2% |
|
MDLN
Medline Inc.
|
$45.62B | -14.8% | +11.5% | — | 3.1% |
|
RMD
Resmed Inc
|
$32.02B | -7.5% | +13.4% | 21.3 | 9.8% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| BAX | +3.1% | -6.2% | +37.7% | +0.9% | +26.7% |
| SPY | +1.2% | +0.6% | +11.6% | +1.6% | +13.6% |
| vs SPY | +1.9% | -6.8% | +26.1% | -0.7% | +13.1% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.